A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes.

Conclusions: LDR brachytherapy is an effective treatment option in low- to intermediate-risk prostate cancer patients. We observed low biochemical relapse rates and minimal GU toxicities several years after treatment in patients with or without TURP. However, a small risk of urinary retention was observed in some patients. PMID: 29789764 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/29789764?dopt=Abstract

Source: Journal of Contemporary Brachytherapy - May 27, 2018 Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research